Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.41 |
| ▸ | MAP1LC3A | Q9H492 | 2/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867048 | 1.00 | LMNA (0.41) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6864423 | 0.91 | HSP90AB1 (0.42) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6864422 | 0.91 | HSP90AB1 (0.42) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6860198 | 0.90 | LMNA (0.41) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6860194 | 0.90 | LMNA (0.41) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6943889 | 0.90 | HSP90AB1 (0.43) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6940657 | 0.90 | LMNA (0.44) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6943894 | 0.90 | HSP90AB1 (0.43) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL6941760 | 0.90 | LMNA (0.44) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A | |
| SCHEMBL7075739 | 0.89 | LMNA (0.45) | LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-6350733-B1 | 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS | AVENTIS PHARMA S.A. (FR) | 2002-02-26 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | LMNA 1772/4885HSP90AB1 1949/4885HSP90AA1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.